---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-024297"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:44:00.038289+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Puma Q2 NERLYNX revenue $44.4M (-14% YoY); GAAP net loss $4.5M vs profit $2.1M

## Summary
- Q2 2024 product revenue $44.4M (down from $51.6M in Q2 2023); total revenue $47.1M incl $2.7M royalties.
- GAAP net loss $4.5M ($0.09 loss per share) vs net income $2.1M ($0.05 EPS) in Q2 2023.
- Non-GAAP adjusted net loss $2.5M ($0.05 loss per share) vs adjusted net income $4.6M ($0.10 EPS).
- Cash & equivalents $96.8M at June 30, 2024; net cash from ops $1.0M in Q2.
- FY2024 guidance: net product revenue $183-190M, net income $12-15M; Q3 net product revenue $50-53M.

## SEC filing metadata
- accession: 0001437749-24-024297
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774924024297/0001437749-24-024297-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774924024297/pbyi20240731_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-024297
- JSON: https://secwatch.observer/filing/0001437749-24-024297.json
- Plain text: https://secwatch.observer/filing/0001437749-24-024297.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.